ClinicalTrials.gg
CompletedNCT06569355Updated Jul 1, 2025

A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population

A Phase 2 interventional study of VCT220 and Placebo in Obesity and Overweight, sponsored by Vincentage Pharma Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Vincentage Pharma Co., Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Dec 2023, registered Aug 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 600 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.

Enrollment
152nd of 502
250 · median 120
Started
2023
with 49 others
Phase 2
52 of 600
17 open now
Registered
297th of 600
by date

Among the 600 studies in Obesity with a site in China, this one is the 152nd largest by enrollment of the 502 interventional ones that give a count, is one of 50 that started in 2023, is one of 52 in phase 2, and was the 297th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

221 of the 600 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

216 more — sign in →

All 221 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

The goal of the study is to assess how VCT220 tablets affect the bodyweight when used once daily in obese or overweight adult participants

Qualified participants will be randomly assigned to one of four groups using a computerized system. Participants will get VCT220 or placebo tablets for 16 weeks and will need to take tablets each morning.

Participants will have 7 clinic visits and a final follow-up visit approximately 14 days after the last study intervention administration.

Read the detailed description

Not provided

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 18-75 years (inclusive) when signing the form;
  2. (BMI) ≥ 28 kg/m2 with or without concomitant diseases; or BMI ≥ 24 kg/m2 and \< 28 kg/m2 combined with at least one of the following concomitant diseases: pre-diabetes (impaired fasting glucose and/or reduced glucose tolerance), hypertension, dyslipidemia, fatty liver, and obstructive sleep apnea syndrome caused by overweight (see Appendix 1 for specific definitions);
  3. Subjects who have undergone diet control or exercise control alone for at least 12 weeks before screening, resulting in a stable weight within 12 weeks before screening (weight change \< 5%, weight change = [maximum weight - minimum weight]/maximum weight; based on subjects' self-report);
  4. Subjects who have no fertility plan and voluntarily take effective measures without any plans to donate sperm or eggs during the study and within 90 days after the end of study;
  5. Subjects who are willing and able to maintain a stable diet and exercise during the study and fill in diary cards on time; 6)Subjects who are able to understand the procedures and methods of this study, willing to complete this study in strict accordance with the clinical study protocol, and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with previously diagnosed obesity caused by endocrine diseases or single gene mutations, including but not limited to hypothalamic obesity, pituitary obesity, hypothyroid obesity, Cushing's syndrome, islet cell tumor, acromegaly, and hypogonadism;
  2. Subjects who have received bariatric surgery or treatment (except for acupuncture for weight loss, liposuction, and abdominal fat removal more than 1 year from the screening period), or plan to receive bariatric surgery to treat obesity during the study, e.g., gastric bypass surgery and gastric banding;
  3. Subjects who are on a weight loss program at screening and are not in the maintenance period (based on subjects' self-report);
  4. Subjects who have previously been diagnosed with type 1 diabetes mellitus, type 2 diabetes mellitus, or other special types of diabetes;
  5. Subjects who have used any GLP-1 receptor agonist (GLP-1RA), GLP-1 related multi-target agonist (e.g., GLP 1/glucose-dependent insulinotropic polypeptide [GIP] dual agonist and GLP 1/glucagon receptor [GCGR] dual agonist), or compound preparations containing GLP 1 agonist;
  6. Subjects who have received any of the following medications or therapies within 12 weeks before screening:

    • Oral or injectable hypoglycemic medications such as dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium glucose cotransporter 2 (SGLT-2) inhibitors, metformin, insulin secretagogues, thiazolidinediones (TZDs), and insulin;
    • Any approved or unapproved weight loss drugs (such as orlistat, lorcaserin, phentermine/topiramate, and naltrexone/bupropion) or Chinese herbal medicines, health care products, meal replacements, etc., affecting body weight;
    • Use of any drugs that might significantly change body weights, including systemic (i.e., intravenous, oral, or intra-articular administration) for more than 1 week; tricyclic antidepressants; antipsychotic or antiepileptic drugs (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine hydrochloride, clozapine, olanzapine, valeric acid and its derivatives, lithium preparations, and thioridazine), etc.;
  7. Subjects who meet any of the following criteria related to cardiac function:

    • History of myocardial infarction, coronary angioplasty or bypass graft, heart valve disorders or cardiac valve prostheses, unstable arrhythmia, unstable angina, , cerebrovascular accident, etc., within 6 months before screening;
    • Class III or IV congestive cardiac failure according to (NYHA) classification;
    • Subjects with serious arrhythmia requiring treatment (such as long syndrome) and not suitable for the clinical study as assessed by the investigator;
    • Poorly controlled hypertension before screening (i.e., systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg);
    • Presence of clinical abnormalities (e.g., QTcF > 450 msec, complete left bundle branch block, signs of acute or unexplained myocardial infarction, ST-segment changes suggestive of myocardial ischemia, second or third degree atrioventricular block, or serious bradyarrhythmia or tachyarrhythmia) by electrocardiography () at screening that might affect the safety of subjects or the interpretation of study results;
    • Resting heart rate > 100 beats/min;
    • Other cardiac function abnormalities with clinical significance judged by the investigator;
  8. Currently with thyroid dysfunction that is not well controlled with a stable dose of medications, or with clinically significant abnormalities noted in thyroid function test results at screening;
  9. History of medullary thyroid cancer, multiple endocrine neoplasia (MEN) syndrome type 2A or 2B or relevant family history (family history is defined as diseases in a first-degree relatives);
  10. Subjects diagnosed with within 5 years before screening (except for cured cutaneous basal cell carcinoma or cervical carcinoma in situ);
  11. History of acute or chronic pancreatitis, symptomatic gallbladder disease (such as multiple gallstones), pancreatic injury, and other high-risk factors that may lead to pancreatitis;
  12. Subjects with clinically significant abnormal gastric emptying (such as gastric outlet obstruction), severe chronic gastrointestinal diseases (active ulcer within 6 months), long-term use of drugs with direct effects on gastrointestinal motility (including but not limited to mosapride, cisapride, etc.), or gastrointestinal surgery (except for polypectomy and appendectomy) within 6 months before screening, who are not suitable for the clinical study as assessed by the investigator;
  13. History of organ transplantation, or previous or current serious diseases;
  14. Subjects who have a history of major surgery within 6 months before screening, or plan to undergo surgery that might affect study completion or compliance;
  15. Subjects with a history of moderate to severe depression and anxiety, or a history of serious mental illness, or a depression screening scale (PHQ-9) score ≥ 15 at screening;
  16. Subjects with previous suicidal tendency or suicidal behavior;
  17. Subjects with any laboratory test parameter meeting any of the following criteria at screening:

    • Glycosylated () ≥ 6.5%;
    • Fasting plasma glucose (FPG) ≥ 7.0 mmol/L;
    • (eGFR) \< 60 mL/min/1.73 m2 as calculated using the CKD-EPI formula;
    • (ALT) and/or aspartate aminotransferase (AST) ≥ 3.0 × (ULN);
    • Total (TBIL) > 1.5 × ULN;
    • Blood amylase or blood lipase > 1.5 × ULN;
    • Fasting triglycerides (TG) > 5.7 mmol/L;
    • Fasting C-peptide \< 0.8 ng/mL (or \< 0.26 nmol/L);
    • Calcitonin ≥ 1.0 × ULN;
    • Hemoglobin (Hb) \< 110 g/L (males) or \< 100 g/L (females);
  18. Subjects who are positive for virus surface antigen (HBsAg) (except for those with hepatitis B virus deoxyribonucleic acid [HBV-DNA] quantitative results lower than the lower limit of reference range and not using anti-hepatitis B virus drugs at screening), receiving anti-hepatitis B virus drugs, positive for virus (HCV) antibody, positive for (HIV) antibody, or positive for treponema pallidum antibody (Tp-Ab) at screening;
  19. Subjects with known allergies to GLP-1 receptor agonists or relevant ;
  20. Subjects who have previously participated in weight loss clinical trials; those who have participated in any clinical trial for drug or medical device (except for weight loss clinical trials) as subjects within 12 weeks before screening, or subjects who have participated in any clinical trials in which the last dose is within 5 half-lives of the product before screening (whichever is longer) (such restrictions are not applicable to the subjects who fail the screening);
  21. Subjects who have donated or lost ≥ 400 mL of blood or have received blood transfusion within 12 weeks before screening;
  22. Subjects with a known or suspected history of alcohol or tobacco addiction, or drug abuse at screening;
  23. Pregnant or lactating women;
  24. Subjects with positive blood pregnancy test results at screening or before randomization (for female subjects of only); 25)Other conditions that make the subject unsuitable for the study as judged by the investigator.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
250 participants (actual)

Study arms

  • Experimental
    80mg dose group

    Participants will receive VCT220 or placebo tables in 2 weeks dose titration period and take the maintanance dose 80 mg from week 3 to week 16.

    Drug: VCT220 · Drug: Placebo

  • Experimental
    120mg dose group

    Participants will receive VCT220 or placebo tables in 4 weeks dose titration period and take the maintanance dose 120 mg from week 5 to week 16.

    Drug: VCT220 · Drug: Placebo

  • Experimental
    160mg dose group fast titration

    Participants will receive VCT220 or placebo tables in 4 weeks dose titration period and take the maintanance dose 160 mg from week 5 to week 16.

    Drug: VCT220 · Drug: Placebo

  • Experimental
    160mg dose group slow titration

    Participants will receive VCT220 or placebo tables in 6 weeks dose titration period and take the maintanance dose 160 mg from week 7 to week 16.

    Drug: VCT220 · Drug: Placebo

Interventions

  • DrugVCT220

    A small molecule GLP-1R agonist tablet, orally administration, once daily

  • DrugPlacebo

    Placebo tablet

06

What researchers measure

Primary outcomes

  1. Percentage change in body weight

    percentage-point

    Time frame: From baseline (week 1) to week 16

Secondary outcomes

  1. Proportion of subjects with weight decrease ≥ 5%

    percentage-point

    Time frame: From baseline (week 1) to week 16

  2. Absolute change in body weight

    measured in kg

    Time frame: From baseline (week 1) to week 16

  3. Absolute change in body mass index (BMI)

    measured in kg/m\^2

    Time frame: From baseline (week 1) to week 16

  4. Absolute change in waist circumference

    measured in cm

    Time frame: From baseline (week 1) to week 16

  5. Change in blood lipid profiles (TC, TG, LDL-C, and HDL-C)

    measured in mmol/L

    Time frame: From baseline (week 1) to week 16

  6. Change in fasting plasma glucose (FPG)

    measured in mmol/L

    Time frame: From baseline (week 1) to week 16

  7. Change in HbA1c (glycated haemoglobin)

    percentage-point

    Time frame: From baseline (week 1) to week 16

  8. Change in fasting insulin

    measured in μIU/mL

    Time frame: From baseline (week 1) to week 16

  9. Change in fasting C-peptide

    measured in ng/ml

    Time frame: From baseline (week 1) to week 16

Other outcomes

  1. Adverse events, including treatment-emergent adverse events (TEAEs), serious adverse events (SAEs)

    Count of events

    Time frame: From baseline (week 1) to week 18

  2. PK analysis-Minimum concentration

    measured in ng/ml

    Time frame: From week 1 to week 12

  3. PK analysis-Maximum concentration

    measured in ng/ml

    Time frame: From week 1 to week 12

  4. PK analysis-Time to maximum concentration

    measured in hour

    Time frame: From week 1 to week 12

  5. PK analysis-Area under the concentration-time curve

    measured in h∙ng/mL

    Time frame: From week 1 to week 12

07

Study locations

1 site
  • Peking University People's Hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Jul 2024, 6 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 6 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2024
First posted
Aug 26, 2024
StartActual
Dec 27, 2023
Primary completionActual
Jul 13, 2024
CompletionActual
Aug 1, 2024
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06569355
Lead sponsor
Vincentage Pharma Co., Ltd
Responsible party
Sponsor
First posted
Aug 26, 2024
Start date
Dec 27, 2023
Primary completion
Jul 13, 2024
Completion
Aug 1, 2024
Last update
Jul 1, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VCT220

Start the discussion